A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Erlotinib; Pazopanib; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 07 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2009 Actual patient number (58) added as reported by ClinicalTrials.gov.